Avanos Medical (NYSE:AVNS) Releases Q4 2024 Earnings Guidance

Avanos Medical (NYSE:AVNS) updated its fourth quarter 2024 earnings guidance on Monday. The company provided earnings per share guidance of 0.380-0.430 for the period, compared to the consensus earnings per share estimate of 0.400. The company issued revenue guidance of $175.0 million-$180.0 million, compared to the consensus revenue estimate of $177.2 million. Avanos Medical also updated its Q4 guidance to $0.38-0.43 EPS.

Avanos Medical Price Performance

AVNS stock opened at $15.80 on Wednesday. The company’s 50 day simple moving average is $17.70 and its 200-day simple moving average is $20.87. The firm has a market capitalization of $726.12 million, a PE ratio of 46.47 and a beta of 0.99. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46. Avanos Medical has a 12 month low of $14.98 and a 12 month high of $25.36.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 3rd.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.